BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> Infection

Alexander C. Schmidt

Gates Medical Research Institute, Cambridge, MA

Lee Fairlie

Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg

Elizabeth Hellström

Be Part Yoluntu Centre, Paarl, South Africa

Angelique Luabeya Kany Kany

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa

Keren Middelkoop

Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Kogieleum Naidoo

Gonasagrie Nair

Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Anele Gela

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa

Elisa Nemes

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa

Thomas J. Scriba

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa

Amy Cinar

Gates Medical Research Institute, Cambridge, MA

Nicole Frahm

Gates Medical Research Institute, Cambridge, MA

Robin Mogg

Gates Medical Research Institute, Cambridge, MA

David Kaufman

Gates Medical Research Institute, Cambridge, MA

Michael W. Dunne

Gates Medical Research Institute, Cambridge, MA

Mark Hatherill

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa